Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could Novavax Be Too Late to the Party to Win in the U.S. COVID Vaccine Market?

TheMotleyFool

0 0

Could Novavax Be Too Late to the Party to Win in the U.S. COVID Vaccine Market?

Novavax (NASDAQ: NVAX) seems to be on its way toward winning U.S. Emergency Use Authorization (EUA) for its COVID-19 vaccine within the next few months. However, the biotech's vaccine is likely to be the fifth one available to Americans. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Novavax could be too late to the party to win in the U.S. market.

Source Fool.com

Like: 0

NVAX

Share